Vildagliptin
Galvus, Jalra, Xiliarx (vildagliptin) is a small molecule pharmaceutical. Vildagliptin was first approved as Galvus on 2007-09-25. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Trade Name | Galvus, Jalra, Xiliarx |
---|---|
Common Name | Vildagliptin |
Indication | type 2 diabetes mellitus |
Drug Class | Dipeptidyl aminopeptidase-IV inhibitors |